Coxina-3

Side Effects of Coxina-3

GI disturbances, pseudomembranous colitis (rare), abnormalities of liver function, fatalities in those with liver disorders, influenza-like symptoms, skin reactions, eosinophilia, transient leucopenia, thrombocytopenia, purpura, shock, drowsiness, headache, ataxia, visual disturbances, menstrual irregularities. Reddish coloured urine and tears. IV: Thrombophloebitis; extravasation following local irritation and inflammation. Potentially Fatal: Hepatitis or shock-like syndrome with hepatic involvement.

Drug Interactions

Increased metabolism of chloramphenicol, clofibrate, dapsone, digoxin, hexobarbitone, ketoconazole and quinidine. Absorption may be decreased when taken with antacids, anticholinergics, opioids and ketoconazole. Increased metabolism of losartan and its active metabolite, diazepam and nitrazepam. Reduces serum levels of aprepitant, atovaquone, bisoprolol, carvedilol, metoprolol, propanolol, buspirone, bunazosin, diltiazem, nifedipine and verapamil. Increased risk of transplant rejection when used with ciclosporin. Decreases effects of tolbutamide, clofibrate, coumarin anticoagulants, diazepam and oral contraceptives. Potentially Fatal: May reduce efficacy of corticosteroids in Addison's disease and induce an addisonian crisis.

Contraindications

Hypersensitivity, jaundice, severe hepatic disease. IM/SC admin. Porphyria. Not to be used for treatment of meningococcal disease.

Mechanism of Action

Rifampicin has a broad-spectrum bactericidal action which inhibits bacterial RNA synthesis by binding to the β subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription. It is commonly used in the treatment of tuberculosis, leprosy and opportunistic atypical mycobacterial infections. Absorption: Readily absorbed from the GI tract (oral); peak plasma concentrations after 2-4 hr. May be reduced and delayed in the presence of food. Distribution: Body tissues and fluids, CSF (increased during meningitis), crosses the placenta and enters into breast milk. Protein-binding: 84-91% Metabolism: Hepatic; converted to 25-O-desacetylrifampicin. Excretion: Via faeces (60% of the dose).

Special Precautions

Impaired hepatic or renal function. Elderly, malnourished or very young patients. Alcoholic patients. Monitor blood counts and liver function regularly. Body fluids may colour orange-red. Discontinue use if thrombocytopenia or purpura occurs. Pregnancy and lactation. Care should be taken during IV admin to prevent extravasation.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.